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An 18-years old African girl, suffered for almost 4 years
of polyarthralgia, joint contractures and a hardcover
appearance of the skin suggestive of scleroderma. The
clinical picture and a high level of CPK suggested Poly-
myositis (PM).
Search for anti nuclear Antibody (ANA) showed
speckled pattern at 1/2500 titre, and subscreening revealed
isolated anti-Ku antibody. This was more often reported
in association with PM - SSc overlap syndrome.
Skin biopsy favored linear scleroderma.
Interestingly, muscle biopsy showed features typical of
dermatomyositis (DM).
No endocrine disorder or underlying mitotic process
was registered.
Corticosteroid therapy was initiated followed by main-
tenance therapy with methotrexate; the outcome was
favorable.
This case illustrates the interest of anti-Ku screening in
the diagnostic work-up. Our observation thus emphasizes
the possible occurrence of isolated anti-Ku antibody
expression in an overlap syndrome comprising SSc-DM
association. Such association/linkage (implicating DM
rather than PM) is, to our knowledge, very rarely well
reported. Moreover, the therapeutic response seems
favorable in such condition.
We found one biopsy-confirmed observation of SSc-
Inflammatory myositis (IM) overlap syndrome in an anti-
Ku positive patient [1,2]. This later case was initially
reported as SSc-PM overlap syndrome. Interestingly, fol-
low-up showed evolution towards typical features of DM,
and hence an overlap syndrome of SSc-DM association.
Thus, our observation highlights the necessity/interest
of biopsy to ascertain the precise nature of myositis in
an overlap syndrome associating SSc and Myositis Clin-
ico-pathological criteria in inflammatory myositis have
been reviewed by Chérin P et al., [3].
Anti-ku Ab is knowingly reported in a context of myo-
sitis. Thus our observation and review of the literature
suggest that in the presence of isolated anti-Ku Ab in a
SSc-Myositis overlap context, muscle biopsy (that should
be done) would tend to show DM (rather than PM) in
association with the SSc. Such a finding may change the
prognosis and the treatment approach of this syndrome.
This can only be demonstrated after elaborate muscle
biopsy in overlap syndromes, with or without the pre-
sence of anti-Ku antibodies.
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